Publication of Annual Report and Accounts

RNS Number : 0186C

MaxCyte, Inc.

16 June 2021

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Publication of Annual Report and Accounts

Gaithersburg, Maryland - 16 June 2021: MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announces that it has published its Annual Report and Accounts for the year ending 31 December 2020.

The Annual Report is available to view on the Company's website at https://investors.maxcyte.com/news-events/documents-presentations and printed copies of the reports have been posted to those shareholders who have elected to continue to receive paper communications.

###

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialisation. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centres focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted pre-clinical and clinical licences to academic and industry customers covering over an estimated 140 programmes, of which an estimated 100 programmes are for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

For further information please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer	[phone]
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden	[phone]
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith	[phone]
Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams	[phone]
Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott / Chris Welsh	[phone] [e-mail]

 

END

 

 

ACSFFFLLRSIELIL